Repligen Corporation
HealthcareNASDAQ:RGEN · NASDAQ Global Select
-$2.74 today
Vol 1.27M · Avg 1.08M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
2.3%
avg 4.4%
ROIC
1.6%
avg 3.7%
ROA
1.7%
avg 5.9%
Analysis
ROE is currently the strongest return metric at 2.3% versus its period average of 4.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Olivier Loeillot | President, Chief Executive Officer & Director | $1.64M | — | 56 | $54,246.00 | 0.10% |
Jason K. Garland | Chief Financial Officer & Chief Compliance Officer | $1.00M | — | 52 | $20,092.00 | 0.04% |
James R. Bylund | Chief Operating Officer | $856,048.00 | — | 62 | $25,423.00 | 0.05% |
Ralf Kuriyel | Senior Vice President of Research & Development | $749,108.00 | — | 68 | $20,062.00 | 0.04% |
Anthony J. Hunt | Advisor | $671,000.00 | — | 62 | $89,062.00 | 0.16% |
Brian Douglass | Senior VP & Chief Product Officer | $638,106.00 | — | 51 | $7,985.00 | 0.01% |
George Scott Jr. | Senior VP & General Counsel | — | — | — | — | — |
Jacob K. Johnson | Vice President of Investor Relations | — | — | — | — | — |
Michael Martino | Chief Information Officer | — | — | — | — | — |
Neil Whitfield | Senior Vice President of Sales | — | — | — | — | — |
Violetta Hughes | Chief Accounting Officer | — | — | 53 | $3,914.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$201,830.40
Sells
22
$12.63M
Net Sentiment
$12.43M
Net selling
Most Active
Hunt Anthony
18 transactions
1–10 of 23
Analysis
Insiders reported 1 buys worth $201,830.40 and 22 sells worth $12.63M over the last 12 months. That adds up to net selling of $12.43M. Hunt Anthony was the most active insider with 18 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -14.6% | +21.9% (15yr)2 analysts |
| Revenue | N/A | N/A | +10.3% | +20.9% (15yr)5 analysts |
| Net Income | N/A | N/A | -12.9% | +26.2% (15yr)5 analysts |
| EBIT | N/A | N/A | +7.5% | +19.8% (15yr)5 analysts |
Analysis
Recent growth has been strongest in Revenue at +10.3% over three years. Forward estimates point to Net Income at +26.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.40B
Globus Medical, Inc.
NYSE:GMED
$10.84B
Baxter International Inc.
NYSE:BAX
$10.77B
Masimo Corporation
NASDAQ:MASI
$9.42B
Charles River Laboratories International, Inc.
NYSE:CRL
$9.03B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.73B
AptarGroup, Inc.
NYSE:ATR
$7.51B
Avantor, Inc.
NYSE:AVTR
$6.41B
Stevanato Group S.p.A.
NYSE:STVN
$4.66B
Who manages RGEN?
Repligen Corporation (RGEN) lists 11 active executives. The top listed executive is Brian Douglass, Senior VP & Chief Product Officer.
Are RGEN insiders buying or selling?
Recent insider activity shows net selling of $14.87M.
Explore More
Continue the stock analysis
Jump to another research area for this company.